Nanoparticles to fight cancer

Anup PatwaBy Anup Patwa,
Associate - Technology and Patent Research at Aranca

View Anup Patwa  profile on LinkedIn

At just 1–100 nanometres in size, Nanoparticles are the next big thing in cancer treatment.

Designed to enter tissues at a molecular level, they can help therapeutic agents pass through biologic barriers, mediate molecular interactions and identify molecular changes.

A bold new platform for cancer diagnostics and therapy, these particles can be used as carriers in a targeted drug delivery approach, minimizing drug-originated systemic toxic effects.

The development and application of engineered nanoparticles to more effectively treat cancer have witnessed significant advancement over the past several decades.

Nanotechnology is a rapidly evolving domain solving various issues associated with conventional drug therapeutics, including poor water solubility, lack of targeting capability, non-specific distribution, systemic toxicity, and low therapeutic index.


Listed Infrastructure – An Attractive Investment Alternative

Subarna PoddarBy Subarna Poddar,
Senior Analyst - Investment Research at Aranca

View Subarna Poddar  profile on LinkedIn

In the current global scenario where traditional asset classes no longer assure stable returns, listed infrastructure is attracting investors in a big way. In 2015, investors have largely been cautious about the equity markets due to expectations of stable growth in the US and the likely interest rate hike by the US Federal Reserve (Fed) amid declining jobless claims and improving consumer sentiment. However, inconsistent economic indicators, the Greek crisis and a slowdown in China impacted returns. Even amid concerns about the global economy, bond yields were at their lowest in most developed economies, making fixed income investments unattractive. Moreover, the continued fall in gold prices more than eroded the safe-haven appeal of the precious metal.

Global fund managers consider real estate an alternative investment avenue for stable returns on their investments, as real estate assets are likely to witness substantial price appreciation. Listed infrastructure, an upcoming segment of the real estate sector, is gradually gaining traction among fund managers due to its monopolistic nature, price inelasticity, stable predicted cash flows, and inflation hedging characteristic. Although these assets are also traded in the form of equities, the underlying asset is immune to default risks due to strong government backing. Furthermore, these equities act as defensive plays during the downturn.

Listed infrastructure assets are largely government or quasi-government owned. The sovereign backing makes ongoing infrastructure projects less likely to default compared with other privately held real estate asset classes. These assets work in a cost plus model; hence, profitability is already hedged. Also, listed infrastructure assets typically enjoy monopoly due to entry barriers set by the local governments, thus maintaining stable cash flows. Demand for these assets is often inelastic to price changes, such as electricity, water, toll, as people continue using these utilities despite tariff changes. Thus, this asset class provides stable returns even during an economic downturn. Although investment in infrastructure is capital intensive, the equity route makes it cheaper, investor friendly and keeps transactions transparent.

Download Report

Weight Reduction Technologies in the Automotive Industry

By Mrinal Pareek
Manager - Technology & Patent Research at Aranca

View Mrinal Pareek profile on LinkedIn

Patents are the undisputable kingmakers in the life sciences industry.

Pharmaceutical giants who enjoyed a fruitful run while their branded drugs brought in billions have reached a precipice however.

The exclusive rights to a number of chemical drugs expired over the past four years, a patent cliff that left some of the biggest drug makers scrambling to stem their revenue loss.

As many biologics are slated to go generic in the coming years, the pharma industry is increasingly looking to reduce its dependence on blockbusters.


Weight Reduction Technologies in the Automotive Industry

Mayur MhapankarBy Mayur Mhapankar
Analyst - Technology & Patent Research at Aranca

View Mayur Mhapankar  profile on LinkedIn

Over the decades, harmful vehicular emissions have shown a negative impact on the environment and human health.

Increasing pollution from the transportation sector has led to strict regulations on major automobile manufacturers to curb the harmful emissions. With stringent regulations and heavy penalties to contend with, automakers are on a constant lookout for different methods and technologies that help curb vehicular emissions.

While the majority of research by automakers and OEMs is focused towards developing low-weight components, their ability to incorporate lightweight materials at an acceptable price is a major developmental challenge.

Download Report

Write to us

refresh captcha


Email us or Call +1 212-995-5890

Aranca Knowledge Center

Find interesting newsletters, articles, reports & other publications along with market news & views that matter

Related Special Reports